University of Cambridge > Talks.cam > Departmental Seminar Programme, Department of Veterinary Medicine > Therapeutic vaccines for cancer and the role of immunomodulatory drugs

  Browse A-Z

Log in

Googledetails Microsoftdetails

🔐 Log In

Information on

Subscribing to talksdetails Finding a talkdetails Adding a talkdetails Disseminating talksdetails Help and Documentationdetails

ℹ️ Information

Therapeutic vaccines for cancer and the role of immunomodulatory drugs

Download to your calendar using vCal

If you have a question about this talk, please contact Suzy Blows .

Cancer vaccines have been in trials for decades but only this year did the first one (for humans) get approved by the FDA . How come so many good phase 2 studies fail to be repeated in a randomised phase 3 trial? Data from a number of studies suggest that non responders are more likely to have high inflammatory markers than responders and that these patients should be excluded from such trials. Pre treatment with anti-inflammatories may convert non responders to responders. Some of these drugs such as the thalidomide analogues (Revlimid) and Gemzar have marked activity on suppressor and regulatory cells. Other chemotherapy agents may also have favourable effects on the immune system and enhance vaccine responses and not inhibit them as previously thought.

This talk is part of the Departmental Seminar Programme, Department of Veterinary Medicine series.

This talk is included in these lists:

Note that ex-directory lists are not shown.

Other lists

Oatley Meeting Room 1, Engineering, Department of Webinar & LT2, Computer Laboratory, William Gates Building. This seminar will be held in a hybrid format at MR 12, Centre of Mathematical Sciences, CB3 0WA. Alternatively you can also join with Zoom (see abstract for Zoom link).

Other talks

Talk TBC Seminars in Cancer title abstract tba Discussion II Discussion I Title to be confirmed
 

© 2006-2025 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity